Thermo Fisher Scientific (NYSE:TMO) saw a minor uptick in its share price on Friday, closing at $469.67, a 0.52% rise from the previous day. This increase outperformed major indexes such as the S&P 500, Dow, and Nasdaq. This comes after a month-long period of underperformance for TMO's shares, which have seen a 7.45% decrease over the past month, underperforming both the Medical sector and the S&P 500.
In line with real-time metrics from InvestingPro, TMO's market cap stands at a robust $183.73 billion, and the company has a P/E Ratio of 31.95. The company's revenue over the last twelve months (LTM2023.Q2) was $43.52 billion, with a gross profit margin of 39.88%. Despite a slight decrease in quarterly revenue growth at -2.58%, the company's dividend yield remains positive at 0.3%, indicating a potential for income generation for investors.
Looking ahead, Zacks Consensus Estimates project TMO's earnings per share (EPS) to be $5.63 for the upcoming earnings announcement on October 25, 2023. This represents a year-over-year growth of 10.83%. On the other hand, quarterly revenue is anticipated to slightly decrease by 0.42% to $10.63 billion.
For the full-year estimates, earnings are expected to be $22.29 per share with revenue projections of $43.52 billion, both marking declines from the prior year. This aligns with InvestingPro Tips, which indicates a declining trend in earnings per share and a recent slowing down in revenue growth.
In terms of investment ratings, TMO holds a Zacks Rank of #3 (Hold), indicating a neutral stance towards the company's stock. The Zacks Rank system has demonstrated a strong track record, with #1 ranked stocks generating an average annual return of +25% since 1988.
Analysts' upward revisions in estimates suggest a positive outlook on TMO's short-term business trends and profitability potential. The company's Forward P/E ratio stands at 20.96, below its industry average, and it holds a PEG ratio of 2.32, which accounts for its projected earnings growth.
Within industry rankings, the Medical - Instruments industry is ranked at 145 in the Zacks Industry Rank, placing it in the bottom half of all industries. Historically, industries rated in the top 50% have outperformed the bottom half by a factor of 2 to 1.
InvestingPro Tips also highlights Thermo Fisher Scientific as a prominent player in the Life Sciences Tools and services industry, with strong returns over the last five years. The company has also been aggressively buying back shares, a move that often boosts investor confidence. For more insights like these, check out InvestingPro's premium service, which offers a wealth of additional tips.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.